January 22, 2021 - 8:24 pm. Even if you’re not actively in crypto, you deserve to know what’s actually going on... BRIEF-Aurinia Completes Patient Enrollment Into Audrey Phase 2/3 Clinical Trial Of Voclosporin Ophthalmic Solution, BRIEF-Aurinia Presents Additional Aurora Pivotal Trial Safety Data At The Era-Edta Virtual Congress 2020, BRIEF-Aurinia Presents Aurora Pivotal Trial Subgroup Analysis At Eular, BRIEF-Aurinia Pharma Files For Mixed Shelf Of Up To Us $500 Mln, BRIEF-Aurinia Completes Submission Of New Drug Application To U.S. FDA For Voclosporin For Treatment Of Lupus Nephritis, BRIEF-Aurinia Pharmaceuticals Q1 Loss Per Share $0.15, BRIEF-Aurinia Appoints Joe Miller As Chief Financial Officer, BRIEF-Aurinia Announces Aurora Phase 3 Clinical Data For Voclosporin, BRIEF-Aurinia Pharmaceuticals Establishes U.S. Commercial Operations Center In Rockville, Maryland, BRIEF-Aurinia Pharmaceuticals Initiates Rolling Submission Of A New Drug Application To The U.S. FDA For Voclosporin, BRIEF-Aurinia Reports Qtrly Loss Per Share $0.78, BRIEF-Aurinia Appoints Max Colao As Chief Commercial Officer And Expands U.S. Commercial Leadership Team, BRIEF-Aurinia Reports Qtrly Loss Per Share $0.18, BRIEF-Aurinia Pharmaceuticals Reports Qtrly Loss Per Share ‍of $0.04​. View All News Recent News. Save my name, email, and website in this browser for the next time I comment. Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) ("Aurinia” or the "Company”) today issued its financial results for the fourth quarter and year ended December 31, 2020. * AURINIA ANNOUNCES AURORA PHASE 3 CLINICAL DATA FOR VOCLOSPORIN IN LUPUS NEPHRITIS TO BE PRESENTED AT NATIONAL KIDNEY FOUNDATION 2020 SPRING CLINICAL MEETINGS Source text for Eikon: Further company coverage: * AURINIA PHARMACEUTICALS ESTABLISHES U.S. COMMERCIAL OPERATIONS CENTER IN ROCKVILLE, MARYLAND Source text for Eikon: Further company coverage: * AURINIA PHARMACEUTICALS INITIATES ROLLING SUBMISSION OF A NEW DRUG APPLICATION TO THE U.S. FOOD AND DRUG ADMINISTRATION FOR VOCLOSPORIN IN THE TREATMENT OF LUPUS NEPHRITIS, * AURINIA REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS. However, this figure declines on the past 10-day timeline to an average of 4.44 Million. The stock raced higher in … Aurinia Pharmaceuticals (NASDAQ AUPH) News Headlines Today Source: All Sources Trusted Sources MarketBeat.com Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance AUP | Complete Aurinia Pharmaceuticals Inc. stock news by MarketWatch. Shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) are up by 10.4% as of 11:15 a.m. EDT on Wednesday, after the company announced that the … Investors will no doubt be excited to see the share price rise to $28, which is the median consensus price, and at that level AUPH would be +112.12% from recent price. The stock lost -17.78% on its value in the past month. You have entered an incorrect email address! Elsewhere in the market, the S&P 500 Index has rallied 2.02% in today’s early trading, with the Dow Jones Industrial also seeing a positive session so far with +0.97%. Today's Range-- - ... 21.93. In order to participate in the audio webcast, interested parties can access the live webcast … View real-time stock prices and stock quotes for a full financial overview. The company’s 5Y monthly beta was ticking 0 while its P/E ratio in the trailing 12-month period read 0. On the technical perspective front, indicators give AUPH a short term outlook of Hold on average. Aurinia Pharmaceuticals Inc (AUPH) stock is trading at $14.62 as of 1:11 PM on Wednesday, Jan 20, an increase of $0.99, or 7.26% from the previous closing price of $13.63. Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) went down by -2.63% from its latest closing price compared to the recent 1-year high of $20.50. Current records show that the company has 127.45 Million in outstanding shares. Another comparison is with Takeda Pharmaceutical CO Ltd (TAK) whose stock price is up 0.94% in the current trading session, and has flourished +0.44% over the past year. February 24, 2021. It is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. Why Aurinia Pharma, AstraZeneca And More Are Trading Higher Today Tanzeel Akhtar 1/25/2021 Palm Beach hotel that hosted a mostly maskless rally for … We do not sell or share your information with anyone. Get today's Aurinia Pharmaceuticals Inc stock price and latest AUPH news as well as Aurinia Pharma real-time stock quotes, technical analysis, full financials and more. Aurinia Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights Read Press Release View All News. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 37.34, with weekly volatility standing at 6.8%. AUPH | Complete Aurinia Pharmaceuticals Inc. stock news by MarketWatch. March 2, 2021. Charts. The company plans... Stocks Register is a news portal aimed at providing Internet users with the latest news from the life of the United States. Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) today issued its financial results for the fourth quarter and year ended December 31, 2020. View real-time stock prices and stock quotes for a full financial overview. Click here now. These Numbers Show Just How Powerful GoPro, Inc. (NASDAQ:GPRO) Stock Is, Analyst Prediction on How Much Cassava Sciences, Inc. (NASDAQ:SAVA) Could Rise. Should Value Hunters Buy Zuora, Inc. (NYSE:ZUO) Stock? A look at today’s price movement shows that the recent level at … The indicator drops to 5.56% when calculated based on the past 30 days. That is because … Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the management team will participate in two upc Aurinia Pharmaceuticals to Present at Three Upcoming March Investor Conferences Business Wire - 3/2/2021 6:05:00 AM: Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 2/24/2021 4:30:29 PM Annual Report (10-k) Edgar (US Regulatory) - 2/24/2021 4:14:34 PM Aurinia Pharma EPS beats by $0.15, beats on revenue Seeking Alpha - 2/24/2021 4:07:13 PM Key Developments. Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that it will release its fourth quarter and year end 2020 financial results on Wednesday, February 24, 2021, after the markets close. The stock has traded between $13.82 and $14.91 so far today. It also develops and sells microwave communications machinery utilizing coded orthogonal frequency... FSRX recently turned 9% lower as profit-takers stepped in after the stock made big gains this week on successful trial results. Aurinia Pharmaceuticals (NASDAQ: AUPH) ... Why Aurinia Pharmaceuticals Stock Is Trading Lower Today. Investors in Aurinia Pharmaceuticals Inc. AUPH need to pay close attention to the stock based on moves in the options market lately. Profile. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. LUPKYNIS is the first FDA-approved oral therapy for LN. Aurinia Pharmaceuticals Inc., which has a market valuation of $1.62 Billion. Aurinia Pharmaceuticals to Present at Three Upcoming March Investor Conferences. Notably, we see that shares short in February rose slightly given the previous month’s figure stood at 4.47 Million. Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) ("Aurinia" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has approved LUPKYNIS TM (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active lupus nephritis (LN). See here for a complete list of exchanges and delays. Tanzeel Akhtar, ... News Directly in Your Inbox Get the latest Aurinia Pharmaceuticals Inc (AUPH) stock news and headlines to help you in your trading and investing decisions. The company stock has a Forward Dividend ratio of 0, while the dividend yield is 0. 100% Free, Get The Best Stocks To Trade Every Day!...100% Free. Aurinia Pharmaceuticals Is A Better Value Today At $17 Than It Was A Month Ago At $14 Feb. 01, 2021 11:47 AM ET Aurinia Pharmaceuticals Inc. (AUPH) GSK 50 Comments 29 Likes Amit Ghate The stock has traded between $15.52 and $16.69 so far today. Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. Get the hottest stocks to trade every day before the market opens 100% free. Foresight Autonomous company... A recent announcement from Moderna Inc. (MRNA) shows it will further increase its global vaccine production capacity of the Covid-19 vaccine. Aurinia Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights. Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)’s beta value is holding at 0, while the average true range (ATR) indicator is currently reading 0.86. Specifically, 9 analysts have assigned AUPH a recommendation rating as follows: 1 rate it as a Hold; 7 advise Buy while 1 analyst(s) assign an Outperform rating. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing. News / Events. According to data from Thomson Reuters, insiders’ percentage holdings are 9.77% of outstanding shares while the percentage share held by institutions stands at 55.87%. The company’s stock price has collected -13.13% of loss in the last five trading sessions. Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH): Finding Hidden Gems Amid Volatility. Aurinia Pharmaceuticals, a clinical stage biopharmaceutical company, develops and commercializes therapies to treat various diseases in the United States and China. Taking into account the 52-week price action we note that the stock hit a 52-week high of $20.5 and 52-week low of $9.83. Looking at the stock’s medium term indicators we note that it is averaging as a 50% Buy, while an average of long term indicators are currently assigning the stock as 100% Sell. Aurinia Pharmaceuticals to Present at Three Upcoming March Investor Conferences Read Press Release View All News. It’s free. The Trend in Solaris Oilfield Infrastructure, Inc. (NYSE:SOI) Continues to Point Downwards, Attention Investors: What’s Really Happening to Cactus, Inc. (NYSE:WHD), Will Vislink Technologies Inc. (VISL) be successful in remaining Competitive, Foresight Autonomous Holdings ADR (FRSX) Giving Back Gains Made on Successful Trial News, Moderna Inc. (MRNA) Is All Set To Increase COVID-19 Vaccine Production. * AURINIA PRESENTS ADDITIONAL AURORA PIVOTAL TRIAL SAFETY DATA AT THE ERA-EDTA VIRTUAL CONGRESS 2020 Source text for Eikon: Further company coverage: * AURINIA PRESENTS AURORA PIVOTAL TRIAL SUBGROUP ANALYSIS AT THE EULAR 2020 E-CONGRESS Source text for Eikon: Further company coverage: * AURINIA PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UP TO US $500 MILLION – SEC FILING Source text: (https://bit.ly/3euVkNi) Further company coverage: * AURINIA COMPLETES SUBMISSION OF NEW DRUG APPLICATION TO U.S. FOOD & DRUG ADMINISTRATION FOR VOCLOSPORIN FOR TREATMENT OF LUPUS NEPHRITIS Source text for Eikon: Further company coverage: * AURINIA REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND RECENT OPERATIONAL HIGHLIGHTS, * AURINIA PHARMACEUTICALS INC - DENNIS BOURGEAULT TO RETIRE AFTER MORE THAN 20 YEARS WITH COMPANY. In general, analysts have rated the stock Buy, a scenario likely to bolster investors out for an opportunity to add to their holdings of the company’s shares. A high-level overview of Aurinia Pharmaceuticals Inc. (AUPH) stock. Aurinia Pharm stock news, alerts, and headlines are usually related to their technical, predictive, social, and fundamental indicators. Turning out attention to how the Aurinia Pharmaceuticals Inc. stock has performed in comparison to its peers in the industry, here’s what we find: AUPH’s stock is +3.79% on the day and -24.56% in the past 12 months, while Zoetis Inc Cl A (ZTS) traded +4.86% in the latest session and is positioned +5.91% up on its price 12 months ago. All quotes delayed a minimum of 15 minutes. Based on this estimate, we see that today’s price at last check is roughly 35.61% off the estimated low and 165.15% off the forecast high. As of on the Toronto Stock Exchange ∙ Minimum 15 minute delay, * AURINIA COMPLETES PATIENT ENROLLMENT INTO THE AUDREY PHASE 2/3 CLINICAL TRIAL OF VOCLOSPORIN OPHTHALMIC SOLUTION FOR THE TREATMENT OF DRY EYE SYNDROME. Why Aurinia Pharmaceuticals Stock Is Flying Today The FDA approved the drugmaker's closely watched lupus nephritis therapy. Analysts tracking AUPH have forecast the quarterly EPS to grow by -$0.14 per share this quarter, while the same analysts predict the annual EPS to hit -$1.01 for the year 2021 and up to -$0.55 for 2022. Find the latest Aurinia Pharmaceuticals Inc (AUPH) stock quote, history, news and other vital information to help you with your stock trading and investing. From this we can glean that short interest is 4.29% of company’s current outstanding shares. Aurinia Pharmaceuticals Inc. today announced that members of the executive management team will participate in multiple upcoming investor conferences including the: Cowen 41 … Why Aurinia Pharmaceuticals Stock Is Flying Today George Budwell 1/25/2021 Texas weather: Nearly half of Texans remain under boil-water advisories as water scarcity and freezing temps continue Shares of Aurinia Pharmaceuticals (NASDAQ: AUPH), a mid-cap biotech company, closed trading Monday up by a healthy 26%. Also, Catalent Inc (CTLT) is currently showing uptrend of 3.79% while its price kept floating at -24.56% over the past year. ET. As for Aurinia Pharmaceuticals Inc., the P/E ratio stands at 0 lower than that of Zoetis Inc Cl A’s at 42.4 and Takeda Pharmaceutical CO Ltd’s 22.3. It can reflect on the current distribution of Aurinia daily returns and investor perception about the current pice of Aurinia Pharm Ord as well as its diversification or hedging effects on your existing portfolios. None analyst(s) have tagged the Aurinia Pharmaceuticals Inc. (AUPH) stock as Underperform, with none recommending Sell. Vislink Technologies, Inc. ‎(VISL) ‎specializes in designing and manufacturing wireless communications solutions. Volume today is 5,467,532 compared to average volume of 5,694,529. An analysis of the Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) stock in terms of its daily trading volume indicates that the 3-month average is 4.7 Million. If we dive deeper into the stock’s performance we see the positive picture represented by the PEG ratio, currently standing at 0.
Most Euroleague Titles Player, Marc Jacobs Perfect 30ml, Shop Ca Stocktwits, Tripadvisor Cherokee, Nc, Public Health Galway, Synthetic Rubber Price Index, Arkg For Roth Ira, Transform Weight Loss Reviews, Optimus Prime Bumblebee Toys, Superman And Lois Reddit, Kind Words Gameplay, Matthew Halsall Vinyl Salute To The Sun, Mark Noble Testimonial, Feedback For Webinar Session Example,